Cargando…

The Role of Everolimus in Renal Cell Carcinoma

Everolimus (RAD001) is an orally administered agent that inhibits the mammalian target of rapamycin serine-threonine kinase. A phase III pivotal trial on everolimus, published in 2008, provided the first evidence for the efficacy of sequential therapy for patients with metastatic clear cell renal ce...

Descripción completa

Detalles Bibliográficos
Autores principales:	Meskawi, Malek, Valdivieso, Roger, Dell’Oglio, Paolo, Trudeau, Vincent, Larcher, Alessandro, Karakiewicz, Pierre I.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Codon Publications 2015
Materias:	Review Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5345521/ https://www.ncbi.nlm.nih.gov/pubmed/28326273 http://dx.doi.org/10.15586/jkcvhl.2015.43

Ejemplares similares

Highlighting the road towards new disease-specific comorbidity indices
por: Dell’Oglio, Paolo, et al.
Publicado: (2020)

Clinical experience and critical evaluation of the role of everolimus in advanced renal cell carcinoma
por: Sun, Maxine, et al.
Publicado: (2011)

Optimal first-line and second-line treatments for metastatic renal cell carcinoma: current evidence
por: Sun, Maxine, et al.
Publicado: (2014)

Most of patients with localized prostate cancer will be treated in the future? | Opinion: Yes
por: Dell’Oglio, Paolo, et al.
Publicado: (2017)

Bladder Cancer and Urothelial Impairment: The Role of TRPV1 as Potential Drug Target
por: Mistretta, Francesco, et al.
Publicado: (2014)

Role of everolimus in the treatment of renal cell carcinoma
por: George, Saby, et al.
Publicado: (2009)

Comment on ‘Validation of a contemporary prostate cancer grading system using prostate cancer death as outcome’
por: Dell'Oglio, Paolo, et al.
Publicado: (2017)

Impact of the COVID-19 Pandemic on Urologic Oncology Surgery: Implications for Moving Forward
por: Guerrieri, Rossella, et al.
Publicado: (2021)

Clinical Use of [-2]proPSA (p2PSA) and Its Derivatives (%p2PSA and Prostate Health Index) for the Detection of Prostate Cancer: A Review of the Literature
por: Abrate, Alberto, et al.
Publicado: (2014)

Five Years of the CC-ERUS Fellowship: A Survey of the Experiences and Post-fellowship Work of the Fellows
por: Beulens, Alexander J.W., et al.
Publicado: (2020)

Outcome of papillary versus clear cell renal cell carcinoma varies significantly in non-metastatic disease
por: Wagener, Nina, et al.
Publicado: (2017)

Clinical use of lenvatinib in combination with everolimus for the treatment of advanced renal cell carcinoma
por: Leonetti, Alessandro, et al.
Publicado: (2017)

Everolimus – a new approach in the treatment of renal cell carcinoma
por: Anandappa, G, et al.
Publicado: (2010)

Sequential Treatment with Pazopanib and Everolimus in Metastatic Renal Cell Carcinoma
por: Rossetti, Sabrina, et al.
Publicado: (2017)

Everolimus in the management of metastatic renal cell carcinoma: an evidence-based review of its place in therapy
por: Buti, Sebastiano, et al.
Publicado: (2016)

Targeted therapies for renal cell carcinoma in Chinese patients: focus on everolimus
por: Tan, Xiaojie, et al.
Publicado: (2015)

Everolimus affects vasculogenic mimicry in renal carcinoma resistant to sunitinib
por: Serova, Maria, et al.
Publicado: (2016)

Hypertension Caused by Lenvatinib and Everolimus in the Treatment of Metastatic Renal Cell Carcinoma
por: Bendtsen, Mathias Alrø Fichtner, et al.
Publicado: (2017)

Synergic Effect of Metformin and Everolimus on Mitochondrial Dynamics of Renal Cell Carcinoma
por: Hong, Seong-Hwi, et al.
Publicado: (2022)

The role of photovaporization of the prostate in small volume benign prostatic hyperplasia and review of the literature
por: Thomas, Dominique, et al.
Publicado: (2019)

Safety and clinical efficacy of everolimus in the treatment of advanced renal cell carcinoma (RCC)
por: Shahani, Rohan, et al.
Publicado: (2010)

Treatment of everolimus-resistant metastatic renal cell carcinoma with VEGF-targeted therapies
por: Grünwald, V, et al.
Publicado: (2011)

Long-term response with everolimus for metastatic renal cell carcinoma refractory to sunitinib
por: Molina, Ana M., et al.
Publicado: (2010)

Everolimus (RAD001) in the Treatment of Advanced Renal Cell Carcinoma: A Review
por: Agarwala, Sanjiv S., et al.
Publicado: (2010)

The use of everolimus in renal-transplant patients
por: Pascual, Julio
Publicado: (2009)

Everolimus and/or Nivolumab-Associated Cytomegalovirus Colitis in a Patient with Metastatic Renal Cell Carcinoma
por: Ismayilov, Rashad, et al.
Publicado: (2022)

Combination of Everolimus with Sorafenib for Solid Renal Tumors in Tsc2(+/−) Mice Is Superior to Everolimus Alone()
por: Yang, Jian, et al.
Publicado: (2017)

Everolimus in Invasive Malignant Renal Epithelioid Angiomyolipoma
por: Guo, Gang, et al.
Publicado: (2021)

Objective assessment of intraoperative skills for robot‐assisted radical prostatectomy (RARP): results from the ERUS Scientific and Educational Working Groups Metrics Initiative
por: Mottrie, Alexandre, et al.
Publicado: (2020)

Urinary Continence Recovery after Retzius-Sparing Robot Assisted Radical Prostatectomy and Adjuvant Radiation Therapy
por: Olivero, Alberto, et al.
Publicado: (2023)

The role of everolimus in liver transplantation
por: Ganschow, Rainer, et al.
Publicado: (2014)

Sorafenib in the management of metastatic renal cell carcinoma
por: Guevremont, C., et al.
Publicado: (2009)

Quality-adjusted Time Without Symptoms or Toxicity (Q-TWiST) for Lenvatinib plus Everolimus Versus Everolimus Monotherapy in Patients with Advanced Renal Cell Carcinoma
por: Lee, Chung-Han, et al.
Publicado: (2021)

Comparison of peri- and intraoperative outcomes of open vs robotic-assisted partial nephrectomy for renal cell carcinoma: a propensity-matched analysis
por: Hoeh, Benedikt, et al.
Publicado: (2023)

The Changes of Lipid Metabolism in Advanced Renal Cell Carcinoma Patients Treated with Everolimus: A New Pharmacodynamic Marker?
por: Pantano, Francesco, et al.
Publicado: (2015)

Immunological effects of everolimus in patients with metastatic renal cell cancer
por: Huijts, Charlotte M, et al.
Publicado: (2017)

Effects of preset sequential administrations of sunitinib and everolimus on tumour differentiation in Caki-1 renal cell carcinoma
por: Santos, C D, et al.
Publicado: (2015)

Phosphorylation of mTOR and S6RP predicts the efficacy of everolimus in patients with metastatic renal cell carcinoma
por: Li, Siming, et al.
Publicado: (2014)

Long-term follow-up of overall survival for cabozantinib versus everolimus in advanced renal cell carcinoma
por: Motzer, Robert J., et al.
Publicado: (2018)

Phase 1 study of everolimus and low-dose oral cyclophosphamide in patients with metastatic renal cell carcinoma
por: Huijts, Charlotte M., et al.
Publicado: (2018)

Cannot write session to /tmp/vufind_sessions/sess_lf76hbokseh56l3nn1h7vr4qop